FACTORS AFFECTING PROGNOSIS AND MORTALITY IN SEVERE COVID-19 PNEUMONIA PATIENTS
Emine Afşin, Muhammed Emin Demirkol, Prof Assoc Emine Afşin, MD Abant Izzet
doi:10.20471/acc.2023.62.01.13
Fatality rate in coronavirus disease 2019 (COVID-19) cases has been reported to be 3.4% worldwide. The aim of this study was to evaluate the factors that determine prognosis and mortality in severe COVID-19 pneumonia patients. Eighty adult patients with severe COVID-19 pneumonia hospitalized and monitored at Izzet Baysal State Hospital (Bolu, Turkey) between August and November 2020 were included in this retrospective single-center study. Demographic and laboratory data, severity of radiological involvement, comorbidities, agents used in treatment, and clinical results were recorded, and data were grouped as survivors and non-survivors. The mean patient age was 67.8±12.6 years. There were 59 (73.8%) male patients. Comorbid diseases were present in 53 (66.3%) patients. There was no significant relationship between patient age, gender, smoking status or presence of comorbidity and mortality (p>0.05). The variables such as pulmonary involvement above 50%, intubation, or ferritin (>434.8 µg/L), troponin I (>14.05 ng/L) and procalcitonin (>0.125 ng/mL) as the sole variables of laboratory data were found to have significant relationship with increased mortality (p<0.05). Mortality was significantly higher in patients using steroid pulse therapy + tocilizumab, steroid pulse therapy + hydroxychloroquine, or solely steroid pulse therapy, while it was significantly lower in patients receiving azithromycin therapy and those in the plasma + steroid pulse therapy group. The severity of pulmonary involvement, intubation, and increase in inflammation markers such as ferritin, troponin and procalcitonin were found to be significantly associated with mortality (p<0.05). Treatment approaches with azithromycin and plasma + steroid pulse therapy were found to reduce mortality.
References
Aktas, A comprehensive review on rational and effective treatment strategies against an invisible enemy; SARS-Cov-2 infection, Exp Biomed Res,
doi:10.30714/j-ebr.2020463629Andrianopoulos, Papathanasiou, Papathanakos, Chaidos, Koulouras, Tocilizumab's efficacy in patients with coronavirus disease 2019 (COVID-19) is determined by the presence of cytokine storm, J Med Virol,
doi:10.1002/jmv.26209Fernandez-Cruz, Ruiz-Antoran, Munoz-Gomez, López, Mills-Sánchez et al., A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob Agents Chemother,
doi:10.1128/AAC.01168-20Furuta, Takahashi, Fukuda, Kuno, Kamiyama et al., In vitro and in vivo activities of anti-influenza virus compound T-705, Antimicrob Agents Chemother,
doi:10.1128/AAC.46.4.977-981.2002Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends,
doi:10.5582/dst.2020.01047Gebhard, Regitz-Zagrosek, Neuhauser, Morgan, Klein, Impact of sex and gender on COVID-19 outcomes in Europe, Biol Sex Differ,
doi:10.1186/s13293-020-00304-9Guaraldi, Meschiari, Cozzi-Lepri, Milic, Tonelli et al., Tocilizumab in patients with severe COVID-10: a retrospective cohort study. Lancet Rheumatol,
doi:10.1016/S2665-9913Guo, Fan, Chen, Wu, Zhang et al., Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol,
doi:10.1001/jamacardio.2020.1017Horby, Lim, Emberson, Dexamethasone in hospitalized patients with COVID-19 -preliminary report, N Engl J Med,
doi:10.1056/NEJMoa2021436Hu, Sun, Dai, Deng, Li et al., Prevalence and severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis, J Clin Virol,
doi:10.1016/j.jcv.2020.1043719Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet,
doi:10.1016/S0140-6736Hung, To, Lee, Lee, Yan et al., Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection, Chest,
doi:10.1378/chest.12-2907Mareev, Orlova, Pavlikova, Matskeplishvili, Krasnova et al., Steroid pulse-therapy in patients with COVID-19, systemic inflammation and risk of venous thrombosis and thromboembolism (WAYFARER Study), Kardiologiia,
doi:10.18087/car-dio.2020.6.n1226Monreal, De La Maza, Natera-Villalba, Beltrán-Corbellini, Rodríguez-Jorge et al., High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study, Eur J Clin Microbiol Infect Dis,
doi:10.1007/s10096-020-04078-1Petrak, Skorodin, Van Hise, Fliegelman, Pinsky et al., Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2, Clin Transl Sci,
doi:10.1111/cts.12894Rubio-Rivas, Padulles, Mitjavila, Riera-Mestre, García-Forero, Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness, Int J Infect Dis,
doi:10.1016/j.ijid.2020.09.1486Sažetak, Uzrokovanom, None
Sherren, Ostermann, Agarwal, Meadows, Ioannou et al., COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review, Br J Anaesth,
doi:10.1016/j.bja.2020.08.050Simonovich, Pratx, Scibona, Beruto, Vallone et al., A randomized trial of convalescent plasma in COVID-19 severe pneumonia, N Engl J Med,
doi:10.1056/NEJMoa2031304Sit, Aktas, Ozer, Kocak, Erkus et al., Mean platelet volume: an overlooked herald of malignant thyroid nodules, Acta Clin Croat,
doi:10.20471/acc.2019.58.03.03Stone, Frigault, Serling-Boyd, Fernandes, Harvey et al., Efficacy of tocilizumab in patients hospitalized with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2028836Wadman, Couzin-Frankel, Kaiser, Matacic, How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes, Science
Wiersinga, Rhodes, Cheng, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19), JAMA,
doi:10.1001/jama.2020.12839Xia, Li, Wu, Wang, Zhu et al., Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion, Blood,
doi:10.1182/blood.2020007079{ 'indexed': {'date-parts': [[2023, 9, 13]], 'date-time': '2023-09-13T00:43:23Z', 'timestamp': 1694565803315},
'reference-count': 0,
'publisher': 'Sestre Milosrdnice University Hospital Center (KBC Sestre milosrdnice)',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2023]]},
'DOI': '10.20471/acc.2023.62.01.13',
'type': 'journal-article',
'created': {'date-parts': [[2023, 9, 11]], 'date-time': '2023-09-11T09:41:05Z', 'timestamp': 1694425265000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Factors Affecting Prognosis and Mortality in Severe COVID-19 Pneumonia Patients',
'prefix': '10.20471',
'author': [{'given': 'Emine', 'family': 'Afşin', 'sequence': 'first', 'affiliation': []}],
'member': '8565',
'container-title': 'Acta Clinica Croatica',
'original-title': [],
'link': [ { 'URL': 'https://hrcak.srce.hr/file/443392',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 9, 11]],
'date-time': '2023-09-11T09:41:24Z',
'timestamp': 1694425284000},
'score': 1,
'resource': {'primary': {'URL': 'https://hrcak.srce.hr/clanak/443392'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023]]},
'references-count': 0,
'URL': 'http://dx.doi.org/10.20471/acc.2023.62.01.13',
'relation': {},
'ISSN': ['0353-9466'],
'subject': ['General Medicine'],
'container-title-short': 'ACC',
'published': {'date-parts': [[2023]]}}
